Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25643988 | 1.00 | NAMPT (0.38) | NAMPTAKR1C3JAK2TBK1JAK1 | |
| SCHEMBL25643957 | 0.92 | NAMPT (0.37) | NAMPTAKR1C3JAK1BTKUSP30 | |
| SCHEMBL26999047 | 0.92 | NAMPT (0.37) | NAMPTAKR1C3JAK1BTKUSP30 | |
| SCHEMBL26999597 | 0.92 | NAMPT (0.37) | NAMPTAKR1C3JAK1BTKUSP30 | |
| SCHEMBL25642298 | 0.92 | NAMPT (0.37) | NAMPTAKR1C3JAK1BTKUSP30 | |
| SCHEMBL25643996 | 0.92 | NAMPT (0.39) | NAMPTAKR1C3JAK1BTKUSP30 | |
| SCHEMBL25642322 | 0.92 | NAMPT (0.39) | NAMPTAKR1C3JAK1BTKUSP30 | |
| SCHEMBL25225074 | 0.88 | NAMPT (0.40) | NAMPTBTKCYP3A4CYP2C9 | |
| SCHEMBL25221361 | 0.88 | NAMPT (0.40) | NAMPTBTKCYP3A4CYP2C9 | |
| SCHEMBL25642242 | 0.88 | NAMPT (0.46) | NAMPTJAK1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | WANG, Zheming (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | Rushi Biotech (Hangzhou) Co., Ltd (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067607-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | NAMPT 1/4885AKR1C3 1604/4885JAK2 1044/4885 |
| US-11873284-B2 | Pyridinylcyanoguanidine derivative and use thereof | NAMPT, NAPRT, NNT | NAMPT 1/4885AKR1C3 1653/4885JAK2 1011/4885 |
| US-20230192615-A1 | Pyridinylcyanoguanidine Derivative and Use Thereof | NAMPT, NAPRT, NNT | NAMPT 1/4885AKR1C3 1653/4885JAK2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.